Heena Sharma Blog

  Bharat Biotech's Covaxin is effective against the Delta and Delta plus variant, a study by the Indian Council of Medical Research and National Institute of Virology has said. The study released on Monday showed that Covaxin provides 65.2 per cent protection against the Delta variant which was first detected in India. The Delta variant which has spread to 99 countries is a variant of concern and was also responsible for the second wave in India. The Delta variant has also been identified as the leading cause of breakthrough infections globally among vaccinated individuals, the study said. The study said that a minor reduction in the neutralising antibody titer in Covid-19 recovered cases and full BBV152 vaccinated and post immunized infected cases was observed but the vaccine was found to be effective against the Delta, Delta AY.1 and B.1.617.3 variants. The study published as a pre-print on bioRxiv said that Sera of vaccines among Covid naïve recovered cases with full vacc...

  India's tally of COVID-19 cases rose to 1,08,38,194, with 11,831 new infections being reported in a day, while the daily death count fell below 100 for the fourth time this month, according to Union Health Ministry data updated on Monday. The death toll increased to 1,55,080 with 84 daily new fatalities, the data updated at 8 am showed. The number of people who have recuperated from the disease surged to 1,05,34,505, pushing the national COVID-19 recovery rate of 97.20 per cent, while the COVID-19casefatality rate stands at 1.43per cent. The COVID-19 active caseload remained below 2 lakh. There are 1,48,609 active coronavirus infections in the country which comprises1.37 per cent of the infection count, the data stated. Read More

  The Convalescent Plasma (CP) therapy didn't help in reducing death due to the coronavirus, the India Council of Medical Research (ICMR) revealed in a study. The apex medical research has made these revelations to investigate the effectiveness of plasma therapy for the treatment of COVID-19 after conducting a study in 39 hospitals across India. For this, the ICMR researchers did an open-label, parallel-arm, phase II, multicentre, and randomized controlled trial from April 22 to July 14 this year. The trial was registered with the Clinical Trial Registry of India (CTRI) for the purpose, it said. A total of 1,210 patients (moderately ill confirmed COVID-19) admitted across 39 trial sites were screened. Of these, 29 were teaching public hospitals and 10 were private hospitals spread across 14 states and Union Territories representing 25 cities. Read More